Program
QL1207H
A development code. Also written as “QL1207H injection”.
Its studies are mostly in Macular Degeneration, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 11 open or running | phase 3since Mar 18, 2026 | Mar 18, 2026 | Dec 2026phase 3 · NCT07489586 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 18, 2026First study: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)First studyNCT07489586 · 356 planned
Ahead
- Dec 2026Primary completion: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)NCT07489586
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07489586Neovascular Age-Related Macular Degeneration (nAMD) | 3 | Not yet recruiting | Dec 2026 | 356 |
How it is read
Names in the registry
- “QL1207H injection”, 1 entry
Codes read as this program: QL1207H.
Conditions, from the studies’ own filings
- Macular Degeneration, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.